Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study

Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study

Abstract Aim To evaluate the efficacy and impact of long-acting injectable (LAI) aripiprazole in patients with schizophrenia with a coexisting substance use disorder (SUD). Patients and methods A multicenter, observational, descriptive and retrospective study was conducted in patients with a DSM-5 d...

Full description

Bibliographic Details
Main Authors:	Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis, Francisco Arias
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2020-02-01
Series:	Drugs - Real World Outcomes
Online Access:	https://doi.org/10.1007/s40801-020-00178-8

Similar Items

Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
by: Nestor Szerman, et al.
Published: (2020-02-01)

A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment
by: Basurte-Villamor I, et al.
Published: (2022-05-01)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
by: Wang SM, et al.
Published: (2014-08-01)

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
by: Daniel Schöttle, et al.
Published: (2018-11-01)

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
by: Daniel Schöttle, et al.
Published: (2018-12-01)

Results of a Hepatitis C Micro-Elimination Program in Two Addiction Centers Among Subjects With Substance Use Disorder
by: Pablo Vega-Astudillo, et al.
Published: (2022-02-01)

The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
by: Hidenobu Suzuki, et al.
Published: (2017-05-01)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
by: Chih-Sung Liang, et al.
Published: (2021-11-01)

Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
by: Oloruntoba Oluboka, et al.
Published: (2023-05-01)

Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen
by: S.L. Romero Guillena, et al.
Published: (2022-06-01)

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
by: De Hert M, et al.
Published: (2015-05-01)

Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study
by: Vanessa Sanchez-Gistau, et al.
Published: (2023-08-01)

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia
by: Michele Wilson, et al.
Published: (2016-03-01)

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
by: Oya K, et al.
Published: (2015-09-01)

Partial Agonists and Dual Disorders: Focus on Dual Schizophrenia
by: Lola Peris, et al.
Published: (2021-12-01)

Treatment persistence with aripiprazole once monthly: a 4-year follow-up
by: Andrea Fagiolini, et al.
Published: (2022-09-01)

Aripiprazole in schizophrenia: consensus guidelines.
by: Travis, M, et al.
Published: (2005)

Review of depot aripiprazole for schizophrenia
by: Motiwala FB, et al.
Published: (2013-11-01)

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
by: Christophe Sapin, et al.
Published: (2016-09-01)

Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study
by: Howard C. Margolese, et al.
Published: (2022-12-01)

Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study
by: José Manuel Olivares, et al.
Published: (2021-01-01)

Schizophrenia: effects of aripiprazole in metabolic syndrome
by: Deborah Galvão Coelho da Silva, et al.
Published: (2019-11-01)

Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly
by: Christoph U. Correll, et al.
Published: (2023-11-01)

Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study – CORRIGENDUM
by: José Manuel Olivares, et al.
Published: (2021-01-01)

BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)
by: Daniel Schöttle, et al.
Published: (2023-03-01)

Aripiprazole-associated tic in a schizophrenia patient
by: Guo X, et al.
Published: (2015-03-01)

Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia.
by: Zhenhe Zhou, et al.
Published: (2013-01-01)

Effect of aripiprazole once-monthly 400mg (AOM400) on hospitalisation prevention and use of healthcare resources in schizophrenia patients, a study based on real clinical practice on schizophrenia: AMBITION Study
by: V. Sanchez-Gistau, et al.
Published: (2023-03-01)

Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies
by: Daniel Schöttle, et al.
Published: (2022-01-01)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
by: Saki Hattori, et al.
Published: (2023-03-01)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
by: Peters-Strickland T, et al.
Published: (2019-06-01)

The use of aripiprazole in early onset schizophrenia: safety and efficacy
by: Ibrahim, Normala, et al.
Published: (2009)

Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
by: Yun Tien, et al.
Published: (2022-07-01)

Treatment of refractory catatonic schizophrenia with low dose aripiprazole
by: Sasaki Tsuyoshi, et al.
Published: (2012-05-01)

Aripiprazole for refractory catatonic schizophrenia – A case report
by: Saisudha N V Gorthi, et al.
Published: (2015-01-01)

Once-monthly paliperidone injection for the treatment of schizophrenia
by: Delia Bishara
Published: (2010-09-01)

Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
by: Joseph R. Calabrese, et al.
Published: (2018-06-01)

Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole
by: Topolov Mariyan K., et al.
Published: (2016-03-01)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
by: El Khoury AC, et al.
Published: (2021-10-01)

Preventive effect of aripiprazole once monthly on rehospitalization for bipolar disorder: A multicenter 1‐year retrospective mirror image study
by: Junichi Goto, et al.
Published: (2023-09-01)